Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Combined With Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
NCT07618910Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- May 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tangdu Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07618910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618910.